Cargando…
COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is paramount. There have been a number of reports stating that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. There...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105332/ https://www.ncbi.nlm.nih.gov/pubmed/32256706 http://dx.doi.org/10.3332/ecancer.2020.1023 |
_version_ | 1783512378489438208 |
---|---|
author | Russell, Beth Moss, Charlotte Rigg, Anne Van Hemelrijck, Mieke |
author_facet | Russell, Beth Moss, Charlotte Rigg, Anne Van Hemelrijck, Mieke |
author_sort | Russell, Beth |
collection | PubMed |
description | Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is paramount. There have been a number of reports stating that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. Therefore, this review aimed to collate information available in published articles to identify any evidence behind these claims with the aim of advising clinicians on how best to treat patients. This review found no published evidence for or against the use of NSAIDs in COVID-19 patients. Meanwhile, there appeared to be some evidence that corticosteroids may be beneficial if utilised in the early acute phase of infection, however, conflicting evidence from the World Health Organisation surrounding corticosteroid use in certain viral infections means this evidence is not conclusive. Given the current availability of literature, caution should be exercised until further evidence emerges surrounding the use of NSAIDs and corticosteroids in COVID-19 patients. |
format | Online Article Text |
id | pubmed-7105332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-71053322020-04-01 COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Russell, Beth Moss, Charlotte Rigg, Anne Van Hemelrijck, Mieke Ecancermedicalscience Short Communication Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is paramount. There have been a number of reports stating that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. Therefore, this review aimed to collate information available in published articles to identify any evidence behind these claims with the aim of advising clinicians on how best to treat patients. This review found no published evidence for or against the use of NSAIDs in COVID-19 patients. Meanwhile, there appeared to be some evidence that corticosteroids may be beneficial if utilised in the early acute phase of infection, however, conflicting evidence from the World Health Organisation surrounding corticosteroid use in certain viral infections means this evidence is not conclusive. Given the current availability of literature, caution should be exercised until further evidence emerges surrounding the use of NSAIDs and corticosteroids in COVID-19 patients. Cancer Intelligence 2020-03-30 /pmc/articles/PMC7105332/ /pubmed/32256706 http://dx.doi.org/10.3332/ecancer.2020.1023 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Russell, Beth Moss, Charlotte Rigg, Anne Van Hemelrijck, Mieke COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? |
title | COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? |
title_full | COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? |
title_fullStr | COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? |
title_full_unstemmed | COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? |
title_short | COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? |
title_sort | covid-19 and treatment with nsaids and corticosteroids: should we be limiting their use in the clinical setting? |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105332/ https://www.ncbi.nlm.nih.gov/pubmed/32256706 http://dx.doi.org/10.3332/ecancer.2020.1023 |
work_keys_str_mv | AT russellbeth covid19andtreatmentwithnsaidsandcorticosteroidsshouldwebelimitingtheiruseintheclinicalsetting AT mosscharlotte covid19andtreatmentwithnsaidsandcorticosteroidsshouldwebelimitingtheiruseintheclinicalsetting AT rigganne covid19andtreatmentwithnsaidsandcorticosteroidsshouldwebelimitingtheiruseintheclinicalsetting AT vanhemelrijckmieke covid19andtreatmentwithnsaidsandcorticosteroidsshouldwebelimitingtheiruseintheclinicalsetting |